{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:27:14Z","timestamp":1793813234577,"version":"4.6.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ir J Med Sci"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s11845-025-04194-x","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T07:35:31Z","timestamp":1763969731000},"page":"131-136","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The metabolic benefits associated with semaglutide use in obese women with polycystic ovary syndrome- a retrospective study of clinical practice"],"prefix":"10.1007","volume":"195","author":[{"given":"Fatimah","family":"Alawami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Novaes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Gibney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niamh","family":"Phelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy Ann","family":"Behan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4256-3314","authenticated-orcid":false,"given":"Lisa","family":"Owens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"issue":"6","key":"4194_CR1","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1210\/jc.2003-032046","volume":"89","author":"R Azziz","year":"2024","unstructured":"Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO (2024) The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metabolism 89(6):2745. https:\/\/doi.org\/10.1210\/jc.2003-032046","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"4","key":"4194_CR2","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/j.1365-2265.1994.tb02578.x","volume":"41","author":"J Holte","year":"1994","unstructured":"Holte J, Bergh T, Gennarelli G, Wide L (1994) The independent effects of polycystic ovary syndrome and obesity on serum concentrations of gonadotrophins and sex steroids in premenopausal women. Clin Endocrinol (Oxford) 41(4):473\u2013481. https:\/\/api.istex.fr\/ark:\/67375\/WNG-WZ7MC35W-J\/fulltext.pdfhttps:\/\/doi.org\/10.1111\/j.1365-2265.1994.tb02578.x","journal-title":"Clin Endocrinol (Oxford)"},{"key":"4194_CR3","doi-asserted-by":"publisher","unstructured":"Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH (2009) The incidence of co-morbidities related to obesity and overweight: A systematic review and meta-analysis. BMC Public Health 9(1). https:\/\/doi.org\/10.1186\/1471-2458-9-88","DOI":"10.1186\/1471-2458-9-88"},{"issue":"4","key":"4194_CR4","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/cen.14421","volume":"95","author":"TM Barber","year":"2021","unstructured":"Barber TM, Franks S (2021) Obesity and polycystic ovary syndrome. Clin Endocrinol 95(4):531. https:\/\/doi.org\/10.1111\/cen.14421","journal-title":"Clin Endocrinol"},{"issue":"2","key":"4194_CR5","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1210\/jc.2014-3415","volume":"100","author":"CM Apovian","year":"2015","unstructured":"Apovian CM, Aronne LJ, Bessesen DH et al (2015) Pharmacological management of obesity: an endocrine society clinical practice guideline. J Clin Endocrinol Metabolism 100(2):342. https:\/\/doi.org\/10.1210\/jc.2014-3415","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"2","key":"4194_CR6","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","volume":"327","author":"DM Rubino","year":"2022","unstructured":"Rubino DM, Greenway FL, Khalid U et al (2022) Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA: J Am Med Association 327(2):138\u2013150. https:\/\/doi.org\/10.1001\/jama.2021.23619","journal-title":"JAMA: J Am Med Association"},{"key":"4194_CR7","unstructured":"Teede H, Tay CT, Laven J et al International evidence-based guideline for the assessment and management of polycystic ovary syndrome 2023"},{"issue":"8","key":"4194_CR8","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1111\/dom.14725","volume":"24","author":"JPH Wilding","year":"2022","unstructured":"Wilding JPH, Batterham RL, Davies M et al (2022) Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metabolism 24(8):1553. https:\/\/doi.org\/10.1111\/dom.14725","journal-title":"Diabetes Obes Metabolism"},{"key":"4194_CR9","unstructured":"Dunaif A, Segal KR, Futterweit W, Dobrjansky A Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome"},{"issue":"5","key":"4194_CR10","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/S1389-9457(02)00033-3","volume":"3","author":"M Gopal","year":"2002","unstructured":"Gopal M, Duntley S, Uhles M, Attarian H (2002) The role of obesity in the increased prevalence of obstructive sleep apnea syndrome in patients with polycystic ovarian syndrome. Sleep Med 3(5):401\u2013404. https:\/\/doi.org\/10.1016\/S1389-9457(02)00033-3","journal-title":"Sleep Med"},{"key":"4194_CR11","unstructured":"Fogel RB, Malhotra A, Pillar G, Pittman SD, Dunaif A, White DP (2024) Increased prevalence of obstructive sleep apnea syndrome in obese women with polycystic ovary syndrome*"},{"issue":"12","key":"4194_CR12","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1093\/humrep\/dew218","volume":"31","author":"G Bozdag","year":"2024","unstructured":"Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO (2024) The prevalence and phenotypic features of polycystic ovary syndrome: A systematic review and meta-analysis. Hum Reprod 31(12):2841. https:\/\/doi.org\/10.1093\/humrep\/dew218","journal-title":"Hum Reprod"},{"issue":"1","key":"4194_CR13","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ygyno.2014.11.012","volume":"136","author":"M Gottschau","year":"2015","unstructured":"Gottschau M, Kjaer SK, Jensen A, Munk C, Mellemkjaer L (2015) Risk of cancer among women with polycystic ovary syndrome: A Danish cohort study. Gynecol Oncol 136(1):99\u2013103. https:\/\/www.clinicalkey.es\/playcontent\/1-s2.0https:\/\/doi.org\/10.1016\/j.ygyno.2014.11.012. S0090825814014759","journal-title":"Gynecol Oncol"},{"issue":"9","key":"4194_CR14","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1093\/humrep\/deg367","volume":"18","author":"PG Crosignani","year":"2003","unstructured":"Crosignani PG, Colombo M, Vegetti W, Somigliana E, Gessati A, Ragni G (2003) Overweight and obese anovulatory patients with polycystic ovaries: parallel improvements in anthropometric indices, ovarian physiology and fertility rate induced by diet. Hum Reprod 18(9):1928. https:\/\/doi.org\/10.1093\/humrep\/deg367","journal-title":"Hum Reprod"},{"key":"4194_CR15","doi-asserted-by":"publisher","unstructured":"Wu L, Fang Q, Wang M et al (2022) Effect of weight loss on pregnancy outcomes, neuronal-reproductive-metabolic hormones and gene expression profiles in granulosa cells in obese infertile PCOS patients undergoing IVF-ET. Front Endocrinol 13. https:\/\/doi.org\/10.3389\/fendo.2022.954428","DOI":"10.3389\/fendo.2022.954428"},{"issue":"4","key":"4194_CR16","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.fertnstert.2007.04.043","volume":"89","author":"D Panidis","year":"2008","unstructured":"Panidis D, Farmakiotis D, Rousso D, Kourtis A, Katsikis I, Krassas G (2008) Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and Orlistat for 24 weeks on insulin resistance and androgen levels. Fertil Steril 89(4):899. https:\/\/doi.org\/10.1016\/j.fertnstert.2007.04.043","journal-title":"Fertil Steril"},{"issue":"4","key":"4194_CR17","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","volume":"6","author":"RE Pratley","year":"2018","unstructured":"Pratley RE, Aroda VR, Lingvay I et al (2018) Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): A randomised, open-label, phase 3b trial. Lancet Diabets Endocrionol 6(4):275\u2013286. https:\/\/doi.org\/10.1016\/S2213-8587(18)30024-X","journal-title":"Lancet Diabets Endocrionol"},{"key":"4194_CR18","unstructured":"Drucker DJ, Nauck MA The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes"},{"key":"4194_CR19","doi-asserted-by":"publisher","unstructured":"Carmina E, Longo RA (2023) Semaglutide treatment of excessive body weight in obese PCOS patients unresponsive to lifestyle programs. JCM 12(18). https:\/\/doi.org\/10.3390\/jcm12185921","DOI":"10.3390\/jcm12185921"},{"key":"4194_CR20","doi-asserted-by":"publisher","unstructured":"Srinivasan D, Lofton HF (2022) Effect of GLP-1 agonists on weight loss in patients with polycystic ovary syndrome and obesity: A single-center study. Obes Pillars 2. https:\/\/doi.org\/10.1016\/j.obpill.2022.100016","DOI":"10.1016\/j.obpill.2022.100016"},{"key":"4194_CR21","doi-asserted-by":"publisher","unstructured":"Ma R, Deng Y, Wang Y, Zhu S, Ding X, Sun A (2021) Short-term combined treatment with exenatide and Metformin for overweight\/obese women with polycystic ovary syndrome. 134(23):2882. https:\/\/doi.org\/10.1097\/cm9.0000000000001712","DOI":"10.1097\/cm9.0000000000001712"},{"issue":"1","key":"4194_CR22","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/dom.13053","volume":"20","author":"S Fr\u00f8ssing","year":"2018","unstructured":"Fr\u00f8ssing S, Nylander M, Chabanova E et al (2018) Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial. Diabetes Obes Metab 20(1):215\u2013218. https:\/\/doi.org\/10.1111\/dom.13053","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"4194_CR23","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1093\/humrep\/dep399","volume":"25","author":"WA March","year":"2009","unstructured":"March WA, Moore VM, Willson KJ, Phillips DIW, Norman RJ, Davies MJ (2009) The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 25(2):544. https:\/\/doi.org\/10.1093\/humrep\/dep399","journal-title":"Hum Reprod"},{"issue":"2","key":"4194_CR24","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.fertnstert.2022.04.027","volume":"118","author":"KE Elkind-Hirsch","year":"2022","unstructured":"Elkind-Hirsch KE, Chappell N, Shaler D, Storment J, Bellanger D (2022) Liraglutide 3\u00a0mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: A randomized placebo-controlled-phase 3 study. Fertil Steril 118(2):371. https:\/\/doi.org\/10.1016\/j.fertnstert.2022.04.027","journal-title":"Fertil Steril"},{"key":"4194_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-015-0161-3","author":"M Jensterle","year":"2015","unstructured":"Jensterle M, Salamun V, Kocjan T, Vrtacnik Bokal E, Janez A (2015) Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: A pilot randomized study. J Ovarian Res. https:\/\/doi.org\/10.1186\/s13048-015-0161-3","journal-title":"J Ovarian Res"},{"key":"4194_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-015-0005-6","author":"H Kahal","year":"2015","unstructured":"Kahal H, Aburima A, Ungvari T et al (2015) The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls. BMC Endocr Disord. https:\/\/doi.org\/10.1186\/s12902-015-0005-6","journal-title":"BMC Endocr Disord"},{"issue":"3","key":"4194_CR27","doi-asserted-by":"publisher","first-page":"E447","DOI":"10.1210\/jc.2013-2007","volume":"99","author":"AE Joham","year":"2013","unstructured":"Joham AE, Ranasinha S, Zoungas S, Moran L, Teede HJ (2013) Gestational diabetes and type 2 diabetes in reproductive-aged women with polycystic ovary syndrome. J Clin Endocrinol Metabolism 99(3):E447. https:\/\/doi.org\/10.1210\/jc.2013-2007","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"7","key":"4194_CR28","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S0026-0495(03)00104-5","volume":"52","author":"CJ Glueck","year":"2003","unstructured":"Glueck CJ, Papanna R, Wang P, Goldenberg N, Sieve-Smith L (2003) Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metab Clin Exp 52(7):908\u2013915. https:\/\/doi.org\/10.1016\/S0026-0495(03)00104-5","journal-title":"Metab Clin Exp"},{"issue":"5","key":"4194_CR29","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1046\/j.1365-2265.2000.01000.x","volume":"52","author":"S Wild","year":"2000","unstructured":"6. Wild S, Pierpoint T, McKeigue P, Jacobs H (2000) Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: A retrospective cohort study. Clin Endocrinol (Oxford) 52(5):595\u2013600. https:\/\/api.istex.fr\/ark:\/67375\/WNG-5GCMZ5KB-2\/fulltext.pdfhttps:\/\/doi.org\/10.1046\/j.1365-2265.2000.01000.x","journal-title":"Clin Endocrinol (Oxford)"},{"issue":"2","key":"4194_CR30","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/j.1365-2265.2006.02587.x","volume":"65","author":"TM Barber","year":"2006","unstructured":"30. Barber TM, Mccarthy MI, Wass JAH, Franks S (2006) Obesity and polycystic ovary syndrome. Clin Endocrinol 65(2):137. https:\/\/doi.org\/10.1111\/j.1365-2265.2006.02587.x","journal-title":"Clin Endocrinol"},{"issue":"8","key":"4194_CR31","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1093\/oxfordjournals.humrep.a136243","volume":"10","author":"AH Balen","year":"1995","unstructured":"Balen AH, Conway GS, Kaltsas G et al (1995) Andrology: polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod (Oxford) 10(8):2107\u20132111. https:\/\/api.istex.fr\/ark:\/67375\/HXZ-RCP08W61-V\/fulltext.pdfhttps:\/\/doi.org\/10.1093\/oxfordjournals.humrep.a136243","journal-title":"Hum Reprod (Oxford)"},{"key":"4194_CR32","doi-asserted-by":"publisher","unstructured":"LEGRO RS (2000) The genetics of obesity lessons for polycystic ovary syndrome. Ann N Y Acad Sci 900(1):193\u2013202. https:\/\/api.istex.fr\/ark:\/67375\/WNG-5R3M6FD9-V\/fulltext.pdfhttps:\/\/doi.org\/10.1111\/j.1749-6632.2000.tb06230.x","DOI":"10.1111\/j.1749-6632.2000.tb06230.x"}],"container-title":["Irish Journal of Medical Science (1971 -)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-025-04194-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11845-025-04194-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-025-04194-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T09:14:48Z","timestamp":1772874888000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11845-025-04194-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["4194"],"URL":"https:\/\/doi.org\/10.1007\/s11845-025-04194-x","relation":{},"ISSN":["0021-1265","1863-4362"],"issn-type":[{"value":"0021-1265","type":"print"},{"value":"1863-4362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"15 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of the authors have any conflict of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}